Article
Dutasteride would offer absolute risk reduction of up to 27% over 2years, study results show
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
What should the adult urologist know about pediatric urologic cancers?
FDA grants de novo authorization to ArteraAI Prostate
FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea
Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD